Research Nester published a report titled “Luteinizing Hormone Releasing Hormone Agonists Market – Global Demand Analysis and Opportunity Outlook 2029″ which delivers detailed overview of the luteinizing hormone releasing hormone agonists market in terms of market segmentation by drug type, patient type, end users, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The market for luteinizing hormone releasing hormone agonists is anticipated to record a significant CAGR over the forecast period, i.e., 2021-2029. The growing adoption of LHRH-agonist for treating patients in neoadjuvant setting dealing with early disease along with the growing usage for the treatment of prostate cancer is fostering the market growth. Further, in initial few weeks LHRH agonist stimulates the production of testosterone and then stop producing new LHRH once elevation level is reached, which in turn, restrains the production of testosterone in body. The drop in the level of testosterone stops the prostate cancer cells from further growing in human body.
Hence, growing incidence rate of prostate cancer is estimated to accelerate the market growth. Based on drug type, the market is segmented into Zoladex, Eligard, Vantas, Lupron and others. The market of all these drugs is estimated to account for noteworthy growth rate owing to the growing demand for these drugs as they are used to treat prostate cancer. Moreover, these drugs help to stop the growth of prostate cancer cells by reducing the production of androgens. These factors are anticipated to propel the market growth over the forecast period.
Based on the regional analysis, the market for luteinizing hormone releasing hormone agonists is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The luteinizing hormone releasing hormone agonists market in North America is estimated to foresee dominance in the region on the account of growing investments in order to develop targeted therapies for the treatment of prostate cancer coupled with the rising cases of prostate cancer in the region.
Request Sample To Learn More About This Report @ https://www.researchnester.com/sample-request-3037
The Asia Pacific region is anticipated to be fastest growing owing to the rising collaborations of various government institutions with major key players in the region for the treatment of prostate cancer. In addition, growing healthcare infrastructure and presence of detailed information related to luteinizing hormone releasing hormone agonists on online portals is fostering the market growth. Moreover, rising awareness programs in various nations for prostate cancer cure is propelling growth of the market.
Clinical Effectiveness of LHRH Agonists to Drive the Market Growth
The growing incidence rate of prostate cancer at earliest stages coupled with the improvement in the chances of living of a person when treated with LHRH agonist therapy combined with surgery is estimated to foster the market growth. Further, LHRH agonists are given by injection under the skin and it stimulates the release of hormones that helps in the production of testosterone. In addition, LHRH agonists are effective in suppressing luteinizing and follicle stimulating hormones leading to its use in the treatment of precocious puberty. Moreover, growing awareness regarding the availability of early treatment of prostate cancer resulting into the improvements in survival of patients is accelerating the market growth.
However, side effects such as impotence, hot flashes and nipple tenderness of using LHRH agonists in treating prostate cancer along with the high cost of treatment is expected to operate as key restraint into the growth of luteinizing hormone releasing hormone agonists market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global luteinizing hormone releasing hormone agonists market which includes company profiling of F. Hoffmann-La Roche Ltd (SWX:RO), Novartis Pharmaceuticals Corporation (SWX:NOVN), Siemens Healthcare Private Limited (ETR:SHL), Pfizer Inc. (NYSE:PFE), Clovis Oncology (NASDAQ:CLVS), Genomic Health, Inc. (NASDAQ:GHDX), Myriad Genetics, Inc. (NASDAQ:MYGN), MDxHealth (EBR:MDXH), Tolmar Pharmaceuticals, Inc. and Ferring B.V. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global luteinizing hormone releasing hormone agonists market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Grab PDF Sample To Learn More About This Report @ https://www.researchnester.com/sample-request-3037
About Research Nester
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
Contact for more Info:
U.S. +1 646 586 9123
U.K. +44 203 608 5919